Drug intelligence / Profile preview

TP-06

Development stage: Phase 2
Lead developer: Tarsus Pharmaceuticals
Modality: Small Molecules
Administration: Ophthalmic

Overview

TP-06 is an investigational ophthalmic solution being developed by Tarsus Pharmaceuticals for the treatment of persistent corneal epithelial defects (PCED). PCED is a rare, serious ocular condition characterized by a non-healing corneal epithelial defect that fails to resolve despite standard-of-care therapies. TP-06 is formulated as a 2.0% topical ophthalmic solution and is currently being evaluated in the Phase 2 'Capellion' clinical trial (NCT07886268) to assess its safety, efficacy, and ability to promote complete corneal healing.

Beyond the preview

Go deeper on TP-06.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TP-06.